Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07738159 Lenvatinib mesylate Neuroendocrine Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07738159 clinical trial report covering Lenvatinib mesylate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2051260134 Infigratinib Phosphate Achondroplasia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
JPRN-jRCT2051260134 clinical trial report covering Infigratinib Phosphate, Phase 2, endpoints, sponsor, geography, readout timing and development white spa
Latest Hotspot
8 min read
NCT07738315 Carboplatin Recurrent Endometrial Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07738315 clinical trial report covering Carboplatin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07739160 HRS-4029 Acute Ischemic Stroke Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07739160 clinical trial report covering HRS-4029, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07738328 Terbinafine Hydrochloride Acute Kidney Injury Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07738328 clinical trial report covering Terbinafine Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07738757 Sacituzumab tirumotecan MSI-H/dMMR Solid Tumors Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07738757 clinical trial report covering Sacituzumab tirumotecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07739459 Zanubrutinib Chronic Lymphocytic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07739459 clinical trial report covering Zanubrutinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07738510 Ofirnoflast Anemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07738510 clinical trial report covering Ofirnoflast, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07738887 Ibrutinib Chronic Lymphocytic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07738887 clinical trial report covering Ibrutinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07740512 Gemfibrozil Sandhoff Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07740512 clinical trial report covering Gemfibrozil, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600129230 Apatinib Mesylate Advanced Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
ChiCTR2600129230 clinical trial report covering Apatinib Mesylate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262950 Salvianic Acid A Sodium Angina, Stable Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
CTR20262950 clinical trial report covering Salvianic Acid A Sodium, Phase 2, endpoints, sponsor, geography, readout timing and development white space.